Cambridge Healthtech Institute’s 16th Annual
Strategies for Targeting Kinases
Novel Chemistries and Techniques for Studying, Modulating, and Degrading Kinases
September 22, 2025
Selectively targeting kinases has always been a challenge, as they possess highly-conserved substrate binding sites and intersect so many different pathways in a cell. However, with developments in technology and emergence of new drug modalities, there has been renewed interest in pursuing kinases involved in cancer, inflammation, autoimmune, neurodegeneration, and other complex disorders. Cambridge Healthtech Institute’s symposium on Strategies for Targeting Kinases highlights emerging assays and molecules that are being developed to selectively modify kinases for targeted therapy.
Coverage will include, but is not limited to:
- Emerging kinase targets (JAK, Aurora, CDK, Rho, WEE1 kinase, Tyrosine kinases)
- Using novel protein degraders, molecular glues for targeting kinases
- Structural and mechanistic techniques for studying kinase biology
- Genomics, proteomics, imaging tools for kinase inhibitor development
- Strategies for targeting covalent, allosteric sites, as well as non-catalytic functions of kinases
- Using AI/ML approaches for pursuing “dark” or understudied kinases
- Computational and MS-based phosphoproteomic profiling for tracking kinase activity
- Exploring ways to improve selectivity, overcome resistance, and improve blood-brain-barrier penetration
The deadline for priority consideration is March 7, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: